Bystander killing effect of DS ‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity-Reference-Cited by-同舟云学术

Bystander killing effect of DS ‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

Published:2016-06-22 Issue:7 Volume:107 Page:1039-1046
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Ogitani Yusuke¹,Hagihara Katsunobu²,Oitate Masataka²,Naito Hiroyuki³,Agatsuma Toshinori¹

Affiliation:

1. Biologics & Immuno‐Oncology Laboratories Daiichi Sankyo Co., Ltd. Tokyo Japan

2. Drug Metabolism and Pharmacokinetics Research Laboratories Daiichi Sankyo Co., Ltd. Tokyo Japan

3. Oncology Laboratories Daiichi Sankyo Co., Ltd. Tokyo Japan

Funder

Daiichi-Sankyo

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.12966

Reference27 articles.

1. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia;Bross PF;Clin Cancer Res,2001

2. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

3. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

4. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

5. Phase I / II study of brentuximab vedotin in J apanese patients with relapsed or refractory CD 30‐positive H odgkin's lymphoma or systemic anaplastic large‐cell lymphoma

Cited by 455 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma;Journal of Gynecologic Oncology;2025

2. Novel antibody-drug conjugates based on DXd-ADC technology;Bioorganic Chemistry;2024-10

3. Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer;Biomedicine & Pharmacotherapy;2024-10

4. Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer;npj Precision Oncology;2024-09-14

5. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance;Nature Reviews Clinical Oncology;2024-09-13